Thyreos Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$1.6M
- Investors
-
7
Thyreos General Information
Description
Operator of a biotech company intended to produce effective prophylactic human health and animal vaccines to treat herpesvirus, recombinant vaccine vectors and oncolytic vectors. The company's new technology is based on a recombinant herpesvirus platform for developing cures to prevent nervous system infections, recurrent disease and produce sterilizing immunity in humans, companion animals, and livestock, enabling doctors to treat viruses and avoid recurrences.
Contact Information
Website
www.thyreosvaccines.comCorporate Office
- 2125 Transformation Drive
- Suite 1000
- Lincoln, NE 68505
- United States
Corporate Office
- 2125 Transformation Drive
- Suite 1000
- Lincoln, NE 68505
- United States
Thyreos Timeline
Thyreos Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Grant | 04-May-2023 | $1.6M | Completed | Generating Revenue | ||
| 7. Seed Round | 12-Dec-2022 | Completed | Generating Revenue | |||
| 6. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 5. Grant | 27-Apr-2022 | Completed | Generating Revenue | |||
| 4. Seed Round | 31-Dec-2020 | Completed | Generating Revenue | |||
| 3. Grant | 01-Dec-2020 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | 01-Jan-2017 | Completed | Startup | |||
| 1. University Spin-Out | 01-Jan-2017 | Completed | Startup |
Thyreos Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed-2 | ||||||||
| Seed |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Thyreos Signals
Thyreos Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| National Institute for Allergy and Infectious Disease | Government | |||
| NIH Seed | Not-For-Profit Venture Capital | |||
| Invest Nebraska | Venture Capital | Minority | ||
| The Nebraska Department of Economic Development | Government | |||
| Matter (Consulting Services (B2B)) | Accelerator/Incubator |
Thyreos FAQs
-
When was Thyreos founded?
Thyreos was founded in 2017.
-
Where is Thyreos headquartered?
Thyreos is headquartered in Lincoln, NE.
-
What is the size of Thyreos?
Thyreos has 5 total employees.
-
What industry is Thyreos in?
Thyreos’s primary industry is Drug Discovery.
-
Is Thyreos a private or public company?
Thyreos is a Private company.
-
What is Thyreos’s current revenue?
The current revenue for Thyreos is .
-
How much funding has Thyreos raised over time?
Thyreos has raised $1.75M.
-
Who are Thyreos’s investors?
National Institute for Allergy and Infectious Disease, NIH Seed, Invest Nebraska, The Nebraska Department of Economic Development, and Matter (Consulting Services (B2B)) are 5 of 7 investors who have invested in Thyreos.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process